白蛋白用于肝性脑病门诊患者的双盲随机安慰剂对照试验:HEAL研究
这项双盲随机安慰剂对照试验纳入48例既往有肝性脑病、当前存在轻微肝性脑病且低白蛋白血症的肝硬化门诊患者,按1:1随机接受每周25%静脉白蛋白1.5 g/kg或生理盐水输注共5周。白蛋白组在输注结束时和研究结束时PHES与Stroop测验的轻微肝性脑病逆转和改善均优于安慰剂组,且仅白蛋白组SIP总分和心理社会领域评分改善,IL-1β和内皮功能障碍标志物显著降低。作者认为白蛋白输注与认知功能及心理社会生活质量改善相关,可能归因于内皮功能障碍的改善。
要点
- 白蛋白组在输注结束时和研究结束时PHES与Stroop测验的轻微肝性脑病逆转和改善均大于安慰剂组。
- 仅白蛋白组SIP总分和心理社会领域评分在输注结束时和研究结束时较基线改善,躯体领域未改善。
- 白蛋白组IL-1β和内皮功能障碍标志物显著降低,不良事件两组相似。
核心结论
- 在既往有肝性脑病且当前存在轻微肝性脑病的肝硬化门诊患者中,白蛋白输注与认知功能及心理社会生活质量改善相关,可能归因于内皮功能障碍的改善。
研究设计与样本
- 双盲、安慰剂对照随机临床试验,纳入48例(每组24例)既往有肝性脑病、当前存在轻微肝性脑病且低白蛋白血症的肝硬化门诊患者,按1:1随机接受每周25%静脉白蛋白1.5 g/kg或生理盐水输注共5周。
主要发现
- 白蛋白组在输注结束时和研究结束时PHES与Stroop测验的轻微肝性脑病逆转和改善均大于安慰剂组,且持续至研究结束。
- 仅白蛋白组SIP总分和心理社会领域评分在输注结束时和研究结束时较基线改善,躯体领域未改善。
- 白蛋白组IL-1β和内皮功能障碍标志物显著降低。
- 白蛋白组白蛋白水平升高、缺血修饰白蛋白降低,仅见于输注结束时和研究结束时较基线。
- 不良事件两组相似,MELD和血氨在组间及组内保持稳定。
关键数值与推荐
- 轻微肝性脑病采用心理测量肝性脑病评分(PHES)、Stroop或临界点击频率定义。
- 生活质量基于疾病影响概况(SIP)总分、躯体领域和心理社会领域评估。
临床怎么用
- 作者认为,对于尽管接受肝性脑病标准治疗但仍存在认知功能障碍和生活质量受损的患者,如果这些结果得到验证,可考虑白蛋白输注。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Even after recovery from overt hepatic encephalopathy (HE), minimal HE (MHE), which impairs quality of life (QoL), can persist. A double-blind, placebo-controlled randomized clinical trial was performed to determine the impact of albumin vs. saline on MHE and QoL in individuals with prior HE already on standard of care. METHODS: Outpatients with cirrhosis and prior HE, MHE and hypoalbuminemia already on treatment for HE were included. Patients on regular IV albumin infusions were excluded. Participants were randomized 1:1 to receive either weekly infusions of 25% IV albumin 1.5 g/kg or saline over 5 weeks. MHE was defined using either psychometric hepatic encephalopathy score (PHES), Stroop or critical clicker frequency. MHE, QoL (based on sickness impact profile [SIP] total, physical, psychosocial domain) and serum markers (inflammation, endothelial dysfunction, and ischemia-modified albumin) were compared between baseline, the final infusion visit (end-of-drug [EOD]) and 1-week post final infusion (end-of-study [EOS]). RESULTS: Forty-eight (24/group) participants were randomized and balanced (including by HE medication use) at baseline. Adverse events were similar, with MELD and ammonia remaining stable between/within groups. Albumin levels increased and ischemia-modified albumin decreased only in the albumin group at EOD and EOS vs. baseline. PHES and Stroop MHE reversal and improvement were greater in the albumin group at EOD and persisted at EOS. SIP total and psychosocial, but not physical, domain improved only in the albumin group at EOD and EOS vs. baseline. A significant reduction in IL-1β and endothelial dysfunction markers was also observed in the albumin group. CONCLUSION: In a double-blind, placebo-controlled trial of outpatients with cirrhosis, prior HE and current MHE, albumin infusions were associated with improved cognitive function and psychosocial QoL, likely due to amelioration of endothelial dysfunction. CLINICAL TRIALS REGISTRATION: www. CLINICALTRIALS: gov NCT03585257. IMPACT AND IMPLICATIONS: Even after recovery from overt hepatic encephalopathy (HE), minimal HE (MHE), which impairs quality of life, can persist. We found that intravenous albumin infusions were associated with improved cognitive function and psychosocial quality of life, likely owing to amelioration of endothelial dysfunction, compared to placebo in outpatients with prior HE and current MHE. In patients who continue to demonstrate cognitive dysfunction and impaired quality of life despite standard of care therapy for HE, albumin infusions could be considered if these results are validated.
引用
- Fagan A, Gavis EA, Gallagher ML, et al. A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study. J Hepatol. 2022. PMID: 36152764. doi:10.1016/j.jhep.2022.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。